🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records — a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the register
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
2024-519010-31-00High-Risk, Surgically Resectable Melanoma
Fondazione Melanoma Onlus
Neoplasms
Italy
15/09/2025
Phase IV
A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants with Chronic Obstructive Pulmonary Disease and Hyperinflation (ORATOS)
2025-521987-37-00Chronic Obstructive Pulmonary Disease
AstraZeneca AB
Respiratory Tract Diseases
Germany
15/09/2025
Phase I/II
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects with Moderate-to-Severe Active Thyroid Eye Disease
2024-514110-12-00Thyroid Eye Disease
Amgen Inc.
Eye Diseases
France, Spain, Italy, Poland, Germany, Greece
15/09/2025
Phase IV
A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
2024-515215-21-00DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands, Italy, Spain, Belgium, Germany
15/09/2025
Phase II
AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial
2025-521686-27-01Major Depression Disorder (MDD), Major Depression
Region Uppsala
Nervous System Diseases
Sweden
15/09/2025
Phase II
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
2024-513155-32-00chronic spontaneous urticaria
Philipps-Universitaet Marburg
Skin and Connective Tissue Diseases
Germany
15/09/2025
Phase I
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00Advanced solid tumors, Breast Cancer
Atavistik Bio Inc.
Neoplasms
Belgium, Italy, Spain, France
15/09/2025
Phase I
A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair
2025-522774-36-00Advanced solid tumors
Nimbus Wadjet Inc.
Neoplasms
Spain, Portugal, France, Ireland
15/09/2025
Phase I
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
2024-519727-18-00Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell …
Eli Lilly & Co.
Neoplasms
Spain, Germany, France
15/09/2025
Phase II
Intraperitoneal irinotecan combined with systemic therapy for patients with gastric peritoneal metastases: A phase II, multicenter study
2025-521468-36-00Gastric peritoneal metastases
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
15/09/2025
Phase II
A phase 2a open-label study to assess the safety, tolerability, and dosing regimen of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) in patients with peripheral arterial occlusive disease and chronic limb-threatening ischemia undergoing endovascular revascularization (HEALING -study)
2025-522390-11-00Peripheral arterial occlusive disease (PAOD), Chronic limb-…
Aplagon Oy
Cardiovascular Diseases
Finland
15/09/2025
Phase II
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2023-509861-19-01Diffuse large B-cell lymphoma (DLBCL), High-grade B-cell ly…
Universitaet Muenster
Neoplasms
Germany, Italy
15/09/2025
Phase II
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial
2024-517565-16-00Resectable Locally Advanced Oral Cavity Squamous Cell Carci…
Fondazione GONO Plus
Neoplasms
Italy
15/09/2025
Phase II
A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma
2025-521205-41-00Diffuse large B-cell lymphoma NOS, follicular lymphoma Grad…
Aalborg University Hospital
Neoplasms
Denmark
14/09/2025
Phase III
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in Europe
2025-520499-24-00Moderate to Severe Platysma Prominence
Merz Aesthetics GmbH
Not possible to specify
Germany, Poland, France, Spain
12/09/2025
Phase I
ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.
2025-520538-49-00Moderate-Severe Hypoxic-Ischaemic Encephalopathy (HIE)
University College London
Nervous System Diseases
Ireland
12/09/2025
Phase II
Dose-finding exploratory study on Azithromycin on senescence in healthy volunteers
2025-522379-26-00Cellular senescence and associated inflammatory status
IRCCS Ospedale Policlinico San Martino
Cell Physiological Phenomena
Italy
12/09/2025
Phase III
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
2025-520792-67-00Patients with advanced, metastatic NSCLC that have not prog…
Leids Universitair Medisch Centrum (LUMC)
Neoplasms
Netherlands
12/09/2025
Phase II
Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study.
2023-509180-24-00vulvar cancer
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Female Urogenital Diseases and Pregnancy Complications
Italy
12/09/2025
Phase II
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis.
2025-520721-21-00Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Germany, Czechia, Hungary, Spain, Poland, Slovakia
12/09/2025
Phase II
"H3RAKLES": Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer
2024-519624-24-00HER3-mutant and HER2-not amplified metastatic breast cancer
Institut Curie
Neoplasms
France
11/09/2025
Phase IV
An open-label, randomized clinical trial comparing Etacizin versus Propafenone in Atrial Fibrillation
2025-521267-13-01Atrial fibrillation
Olpha AS
Cardiovascular Diseases
Latvia
11/09/2025
Phase II
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
2025-520676-26-00Non-small cell lung cancer (NSCLC)
Fondazione Ricerca Traslazionale
Neoplasms
Italy
11/09/2025
Phase I/II
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants with Advanced Solid Tumours
2024-518281-27-00Gastric Cancer, Gastroesophageal Junction Cancer, Biliary T…
AstraZeneca AB
Neoplasms
Germany
11/09/2025
Phase I
A Phase 1/1b Study of IAM1363 in HER2 Cancers
2024-519188-17-00Relapsed/refractory malignancy with documented diagnosis of…
Iambic Therapeutics Inc.
Neoplasms
Spain, France, Ireland, Italy, Netherlands
11/09/2025
Phase I
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
2025-522921-37-00inteneded for treatment of - active rheumatoid arthritis in…
Gebro Pharma GmbH
Skin and Connective Tissue Diseases
Czechia
11/09/2025
Phase IV
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)
2025-521260-35-00acute ischemic stroke and atrial fibrillation (AF)
University Medical Center Hamburg-Eppendorf
Cardiovascular Diseases
Spain, Germany, Netherlands
11/09/2025
Phase I
A study in healthy people to test whether BI 3000202 affects how 2 other medicines (rosuvastatin and digoxin) are taken up in the body
2025-520656-29-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
11/09/2025
Phase I
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants
2025-522287-32-00Depression, Cognitive dysfunction, Alzheimer’s disease
AlzeCure Pharma AB
Mental Disorders
Sweden
10/09/2025
Phase I
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the comparative bioavailability of Test Product Dapagliflozin/metformin hydrochloride 5 mg/1000 mg film-coated tablets to Reference Product Xigduo 5 mg/1000 mg film-coated tablets in healthy adult male and female subjects under fed conditions.
2025-522254-39-00Bioavailability study in healthy volunteers under fed condi…
Laboratorios Cinfa S.A.
Not possible to specify
Czechia
10/09/2025
Phase I
Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.
2025-523137-25-00Comparative bioequivalence study in healthy volunteers unde…
MEDITOP Gyogyszeripari Kft.
Cardiovascular Diseases
Czechia
10/09/2025
Phase II
A randomized, open label, multicenter, Phase 2 study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® in combination with mFOLFOX6 and bevacizumab versus standard of care for first-line treatment of non-MSI-H/dMMR, PD-L1 positive advanced colorectal cancer.
2024-519590-19-00PD-L1 positive advanced colorectal cancer
Ono Pharmaceutical Co. Ltd.
Neoplasms
Spain, France, Italy
10/09/2025
Phase III
Vitamin D as add-on treatment option of pneumonia and sepsis in elderly subjects (TreatViD)
2024-515978-27-00Sepsis, Pneumonia due to a presumed infection
Azienda Ospedaliero-Universitaria Maggiore Della Carita
Virus Diseases
Italy
10/09/2025
Phase II
A phase 2, multi-center study consisting of a randomized, placebo-controlled period, followed by an open-label extension period to assess the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa
2024-519736-17-00Hidradenitis Suppurativa
Zura Bio Inc.
Immune System Diseases
Poland, Germany, Spain, Hungary
10/09/2025
Phase II
Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin
2024-514327-42-00Advanced neuroendocrine carcinomas (NECs) of the digestive …
Grupo Espanol De Tumores Neuroendocrinos
Neoplasms
Spain, France
10/09/2025
Phase I
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
2025-522331-34-00locally advanced or metastatic ER+/HER2- breast cancer
Pfizer Inc.
Neoplasms
Belgium
09/09/2025
Phase IV
Optimising TREATment for severe Gram-Negative Bacterial infections.
2025-521476-65-00Severe Gram-Negative Bacterial infections
Fundacion Para La Gestion De La Investigacion En Salud De Sevilla
Bacterial Infections and Mycoses
Spain
09/09/2025
Phase I
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
2024-518012-39-00Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Ca…
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain
09/09/2025
Phase IV
Low Intervention, Open, Multicentric, Phase IV Exploratory Clinical Trial to evaluate new biomarkers for the diagnosis and treatment monitoring of tuberculosis
2025-522235-34-00Bacterial pneumonia patients, Pulmonary tuberculosis patien…
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
Bacterial Infections and Mycoses
Spain
09/09/2025
Phase IV
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.
2025-520802-37-00Type 2 diabetes mellitus
Universita' Degli Studi Di Napoli Federico II
Nutritional and Metabolic Diseases
Italy
09/09/2025
Phase II
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2025-520488-42-00Moderate-to-Severe Chronic Obstructive Pulmonary Disease (C…
Upstream Bio Inc.
Respiratory Tract Diseases
Romania, Lithuania, Hungary, Spain, Bulgaria, Ireland, Germany, Latvia, Czechia, Poland, Slovakia
09/09/2025
Phase IV
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial
2025-522506-20-00Depression
Region Hovedstaden
Nervous System Diseases
Denmark
09/09/2025
Phase IV
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD
2025-522503-18-00Chronic kidney disease
Region Midtjylland
Pathological Conditions, Signs and Symptoms
Denmark
09/09/2025
Phase II
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients with Systemic Lupus Erythematosus with or without Active Lupus Nephritis
2024-519930-22-00Systemic Lupus Erythematosus (SLE) With or Without Active L…
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy
09/09/2025
Phase II
Phase 2 Study of Zelenectide Pevedotin in Participants with Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
2025-521115-40-00Advanced or Metastatic Non-small Cell Lung Cancer
Bicycletx Limited
Neoplasms
Italy, Spain, France, Germany
09/09/2025
Phase II
A Phase 2a randomized, observer-blind, study to evaluate the immunogenicity and safety of mRNA-based multivalent seasonal influenza vaccine candidates in adults 18 years of age and older.
2025-522278-35-00Influenza, Human
GlaxoSmithKline Biologicals
Virus Diseases
Belgium
09/09/2025
Phase I/II
A Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A), for the Treatment of Ventilator-Associated Pneumonia
2025-521533-85-00Ventilator-Associated Pneumonia
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.
Bacterial Infections and Mycoses
Portugal, Netherlands
09/09/2025
Phase II
GRACIE : Phase II study evaluating ivonescimab in combination with chemotherapy for first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients
2025-520694-39-00Metastatic or locally advanced irresectable (stage IV) gast…
Unicancer
Neoplasms
France
08/09/2025
Phase III
A Phase 3 Randomized, Controlled Study to Assess the Efficacy and Safety of NVD003 compared with Iliac Crest Bone Graft in Pediatric Participants Treated Surgically for Congenital Pseudarthrosis of the Tibia
2025-520998-39-00Congenital pseudarthrosis of the tibia
Novadip Biosciences
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Belgium
08/09/2025
Phase I
Long-Term Follow-up of AvenCell-Sponsored CAR-T Cell Clinical Trials
2025-521717-67-00Acute myeloid leukemia
Avencell Therapeutics Inc.
Hemic and Lymphatic Diseases
Germany
08/09/2025
Phase II
Phase II randomized clinical trial for evaluating the safety and feasibility of fecal microbiota transplant (FMT) in stage II-III non-small cell lung cancer (NSCLC) patients, using immune checkpoint inhibitors (ICI) responders as donors. MIGRANT GECP 24/02
2025-521251-24-00Non-Small cell lung cancer (NSCLC)
Fundacion GECP
Neoplasms
Spain
08/09/2025
Phase II
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
2024-518465-10-00Multiple Autoimmune Glomerular Diseases
Vera Therapeutics Inc.
Pathological Conditions, Signs and Symptoms
Germany, France, Italy, Spain, Poland, Belgium
08/09/2025
Phase I
A randomised, open label, three periods, three-treatment crossover study to evaluate the pharmacokinetics of alendronic acid oral formulations after single dose administration in healthy volunteers under fasted conditions: a pilot study
2025-522606-20-00Pharmacokinetic study in healthy volunteers under fasted co…
Faes Farma S.A.
Musculoskeletal Diseases
Czechia
08/09/2025
Phase I
The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the treatment of type 2 diabetes mellitus when the condition cannot be adequately controlled by diet and exercise alone.
2025-522975-27-00Not applicable (submitted trial is a BE study in healthy su…
Adamed Pharma S.A.
Nutritional and Metabolic Diseases
Czechia
08/09/2025
Phase II
A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Spasticity in Participants with Multiple Sclerosis (BALANCE-MSS-1)
2024-517745-14-00Multiple Sclerosis Spasticity
Celgene Corp.
Immune System Diseases
Germany, Czechia, Poland
08/09/2025
Phase III
An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study
2025-521096-31-00Chronic Hepatitis C Virus (HCV) Infection
Atea Pharmaceuticals Inc.
Virus Diseases
Romania, France, Germany, Greece, Poland, Spain
08/09/2025
Phase III
A prospective, controlled, randomized, double blind, 2-arms, parallel-group, multicentre, phase 3 study to investigate effectiveness of Actisoufre nasal spray in a pressurized container compared to placebo in female and male adult and paediatric population over 6 years old with acute rhinitis, rhinopharyngitis and rhinosinusitis not requiring antibiotic therapy.
2024-516284-90-00rhinosinusitis not requiring antibiotic therapy, rhinophary…
Laboratoires Grimberg
Respiratory Tract Diseases
Poland
08/09/2025
Phase III
Comparing high and lOw-dose asPirin with dual anTIplatelet therapy for three Months using prasUgrel and aSpirin following Coronary Artery Bypass Grafting. (OPTIMUS-CABG trial).
2025-521892-30-00Primary isolated CABG patients with stable coronary artery …
Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa Religi Medinet Sp. z o.o.
Cardiovascular Diseases
Poland
08/09/2025
Phase II
Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors
2025-522559-25-00Xerostomia due to readiotherapy for a head & neck cancer
Rigshospitalet
Neoplasms
Denmark
08/09/2025
Phase III
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
2024-517524-18-00Patients with moderate-to-severe allergic rhinitis / rhinoc…
ROXALL Medizin GmbH
Immune System Diseases
Germany
05/09/2025
Phase I
A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimer’s disease and Parkinson’s disease.
2024-520142-32-00Cryopyrin associated periodic syndrome
Nodthera Limited
Immune System Diseases
Netherlands
05/09/2025
Phase II
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants with Type 2 Diabetes Mellitus
2024-520322-11-00Type 2 Diabetes Mellitus (T2D)
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Spain, Hungary
05/09/2025
Phase IV
Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement in breast cancer.
2025-521810-24-00Breast cancer
Fundacion Ribera Salud
Diagnosis
Spain
05/09/2025
Phase IV
EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study
2024-520068-32-00Type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany, Italy
05/09/2025
Phase III
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
2025-521478-32-00PEDIATRIC ACUTE MYOCARDITIS
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
04/09/2025
Phase I
Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study
2025-521770-34-00Chronic pulmonary aspergillosis
Radboud universitair medisch centrum Stichting
Bacterial Infections and Mycoses
Netherlands
04/09/2025
Phase I
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
2025-522368-34-00Alzheimer’s Disease
Muna Therapeutics ApS
Nervous System Diseases
Netherlands
04/09/2025
Phase III
The efficacy and safety of Intramuscular Methylprednisolone in patients with Hand OsteoArthritis: the IMHOA trial
2024-518344-20-00Hand osteoarthritis
Sint Maartenskliniek Stichting
Immune System Diseases
Netherlands
04/09/2025
Phase III
adIVO – A phase II trial of ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma
2024-520219-42-00ivosidenib maintenance after SOC adjuvant chemotherapy in c…
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Digestive System Diseases
Germany
04/09/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
2024-518296-56-00Crohn’s Disease
Merck Sharp & Dohme LLC
Digestive System Diseases
Spain, Austria, Lithuania, France, Belgium, Germany, Sweden, Czechia, Finland, Croatia, Latvia, Portugal, Netherlands, Italy, Denmark, Slovakia, Romania, Poland, Ireland, Hungary, Greece
03/09/2025
Phase IV
PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PETERPEN)
2024-518583-13-00Patients with bacteremia
Azienda Ospedaliero Universitaria Di Modena
Bacterial Infections and Mycoses
Italy
03/09/2025
Phase II
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
2024-519573-19-00melanoma
Centre Hospitalier Regional Universitaire
Skin and Connective Tissue Diseases
France
02/09/2025
Phase III
GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas
2024-515948-23-00Advanced pulmonary or gastroenteropancreatic poorly differe…
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
02/09/2025
Phase IV
Evaluation of the effect of adrenalized lidocaine with or without bicarbonate on early postoperative recovery in ambulatory hand and foot surgery with WALANT: A Single-centre prospective randomised double-blind non-inferiority study.
2024-519650-36-00Hand Surgery, Foot surgery
Centre Hospitalier Universitaire De Nimes
Anesthesia and Analgesia
France
02/09/2025
Phase III
The POWER trial: A randomised, two-armed open label phase 3 clinical trial on personalised dose optimisation with adjuvant tamoxifen therapy after breast cancer to investigate the impact on discontinuation and efficacy compared to standard of care
2025-522240-40-00Breast Cancer
Karolinska Institutet
Not possible to specify
Sweden
02/09/2025
Phase I
A study in healthy people to compare how 2 different formulations of survodutide are taken up by the body
2025-522325-35-00Healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Germany
02/09/2025
Phase II
Impact of Glucagon on Physical Capacity and Metabolism
2025-521835-35-00Heart Failure with preserved Ejection Fraction (HFpEF) with…
Katholisches Klinikum Bochum gGmbH
Nutritional and Metabolic Diseases
Germany
02/09/2025
Phase I
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
2025-521295-60-00Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly & Co.
Nervous System Diseases
Belgium, Spain, Netherlands, Germany
02/09/2025
Phase II
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis
2024-520302-19-00Atopic dermatitis
Aclaris Therapeutics Inc.
Skin and Connective Tissue Diseases
Poland, Czechia, Germany
02/09/2025
Phase I
Long-term follow-up of patients treated with GD2IL18CART
2025-521497-34-00Neuroblastoma, Advanced breast cancer, Ewing sarcoma, Osteo…
Universitaet Muenster
Neoplasms
Germany
02/09/2025
Phase III
A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)
2024-516805-22-00Major Depressive Disorder
Cybin IRL Limited
Mental Disorders
Greece, Poland, Ireland, Germany, Czechia
02/09/2025
Phase IV
REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients (REVIDAH study)
2025-521694-14-00Patients with diagnosis of Pulmonary Arterial Hypertension …
Consorci Mar Parc De Salut De Barcelona
Cardiovascular Diseases
Spain
02/09/2025
Phase II
A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)
2024-516909-23-00Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca AB
Neoplasms
Italy, Spain
01/09/2025
Phase III
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
2024-519827-16-00Newly Diagnosed Transplant Ineligible Multiple Myeloma Pati…
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Neoplasms
Norway, Denmark, Spain, Sweden, Austria, Netherlands, Greece, Germany, Italy, Belgium, Portugal, Estonia, Croatia, Ireland, Czechia, Finland
01/09/2025
Phase III
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
2024-520050-38-00Extensive stage small cell lung cancer (ES-SCLC). …
Amgen Inc.
Neoplasms
Portugal, Germany, Spain, Italy, Denmark, Netherlands, France, Austria, Greece, Belgium, Hungary, Poland, Romania
01/09/2025
Phase I
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.
2025-522106-20-00ulcerative colitis
Sun Pharmaceutical Industries Limited
Digestive System Diseases
Romania
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine (MINT-C)
2024-515682-34-00Chronic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Spain, Denmark, France, Germany, Slovakia, Austria, Italy, Poland, Czechia
01/09/2025
Phase I
PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI
2024-517047-30-01Pseudomyxoma Peritonei
Oslo University Hospital HF
Neoplasms
Norway
01/09/2025
Phase III
A phase 3, randomised, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin therapy (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)
2024-512177-27-01High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-m…
Ferring Pharmaceuticals A/S
Male Urogenital Diseases
Spain, Denmark, Poland, Czechia, France
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine (MINT-E)
2024-515715-22-00Episodic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Italy, Austria, Poland, Germany, France, Spain, Slovakia, Denmark, Czechia
01/09/2025
Phase I
OMTX705-006 Phase 1b
2025-521872-69-00Advanced/Metastatic Pancreatic Adenocarcinoma
Oncomatryx Biopharma S.A.
Neoplasms
Spain
01/09/2025
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00Hidradenitis suppurativa (HS)
MoonLake Immunotherapeutics AG
Skin and Connective Tissue Diseases
Norway, Hungary, Spain, France, Germany, Poland, Czechia, Slovakia, Bulgaria, Netherlands, Italy, Portugal, Belgium
29/08/2025
Phase III
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Ulcerative Colitis
2024-514695-41-00Ulcerative Colitis
AbbVie Deutschland GmbH & Co. KG
Digestive System Diseases
Sweden, Greece, Germany, Italy, Belgium, Spain
29/08/2025
Phase III
Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD
2024-516610-38-00Parkinson's disease, Prodromal phase of Parkinson's disease
Institut National De La Sante Et De La Recherche Medicale
Nervous System Diseases
France
29/08/2025
Phase III
A Double-Blind, Randomized, Active Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
2024-518588-36-00Refractory or Relapsed Multiple Myeloma
Celltrion Inc.
Neoplasms
Spain, Poland
29/08/2025
Phase I
A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 in Healthy Participants
2025-520616-33-00Not Applicable
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
29/08/2025
Phase IV
Eficacy of epidural analgesia initiated with dural puncture epidural technic for labour with ultra-low concentration of levobupivacaine 0.0625% (walking epidural). Impact on anaesthetic and obstetric outcomes.
2025-522071-28-00Pregnant women who enter in the delivery room and request e…
Hospital Universitario La Paz
Anesthesia and Analgesia
Spain
29/08/2025
Phase I
Etude de bioéquivalence entre Circadin et Melatonin PILEJE LP 2 mg
2024-519932-17-00Primary insomnia characterized by poor quality of sleep
Pileje
Hormonal diseases
France
28/08/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
2024-520195-94-00BP-I mania or mania with mixed features
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Slovakia, Spain, Croatia, Sweden, Romania
28/08/2025
Phase I
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
2024-519157-10-00Systemic Lupus Erythematosus, Sjogren's disease
AbbVie Deutschland GmbH & Co. KG
Immune system processes
Netherlands, France
28/08/2025
Rows per page Showing 2401–2500 of 2500
Previous 23 24 25
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe?page=25

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.